|Year : 2019 | Volume
| Issue : 8 | Page : 562-566
Optimization of secreted recombinant human epidermal growth factor production using pectate lyase B from Escherichia coli BL21(DE3) by central composite design and its production in high cell density culture
Sriwidodo Sriwidodo1, Toto Subroto2, Iman P Maksum2, Nasrul Wathoni1, Tina Rostinawati3, Himmatul Ulya3, Indah U Putri3
1 Department of Pharmaceutic and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia
2 Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia
3 Department of Biology Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia
|Date of Submission||19-Sep-2019|
|Date of Acceptance||01-Nov-2019|
|Date of Web Publication||30-Dec-2019|
M.Si. Apt. JI. Raya Bandung, Sumedang KM.21, Sumedang 45363, Jawa Barat.
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Context: Human Epidermal Growth Factor (hEGF) is a potential therapeutic protein that has been widely used as a healing agent for various chronic wounds. It induces the proliferation and metabolism of epithelial cells, regenerates skin cells, and validates skin elasticity. In the previous study, recombinant hEGF (rhEGF) had been successfully expressed extracellularly in Escherichia coli (E. coli) BL21 (DE3) using pectate lyase B (PelB) signal peptide. The previous study has shown that the medium concentration and the induction time influenced the production of rhEGF. Aims: Therefore, this study was conducted to optimize the induction time and medium concentration for rhEGF extracellular secretion then followed by scale-up production. Settings and Design: This experiment was carried out using E. coli BL21 (DE3) which contains pD881 plasmid that carries hEGF and PelB gene. Optimization design of induction time and medium concentration were obtained using Central Composite Design (CCD). Methods and Material: The method of study started by the rejuvenation of E. coli culture, extracellular secretion, and optimization in the flask scale then followed by scaled-up production with high-cell density culture in the fermenter. Statistical analysis used: The optimization was carried out using Response Surface Methodology (RSM) and multi regression analysis. Results: This work showed that the multiplication of 1.5-fold medium concentration with induction time 3h after the culture started gave the best result among another condition in this study. Additionally, the rhEGF production in the fermenter scale was identified by SDS-PAGE Tricine and quantified by ELISA, which showed 122.40 μg of the rhEGF per milliliter medium. Conclusions: In respect of the result, we conclude that the optimized condition of extracellular secretion was successfully obtained, and gives higher result before the previous study.
Keywords: Central composite design, Escherichia coli BL21(DE3), high cell-density culture, recombinant human epidermal growth factor
|How to cite this article:|
Sriwidodo S, Subroto T, Maksum IP, Wathoni N, Rostinawati T, Ulya H, Putri IU. Optimization of secreted recombinant human epidermal growth factor production using pectate lyase B from Escherichia coli BL21(DE3) by central composite design and its production in high cell density culture. J Pharm Bioall Sci 2019;11, Suppl S4:562-6
|How to cite this URL:|
Sriwidodo S, Subroto T, Maksum IP, Wathoni N, Rostinawati T, Ulya H, Putri IU. Optimization of secreted recombinant human epidermal growth factor production using pectate lyase B from Escherichia coli BL21(DE3) by central composite design and its production in high cell density culture. J Pharm Bioall Sci [serial online] 2019 [cited 2022 May 29];11, Suppl S4:562-6. Available from: https://www.jpbsonline.org/text.asp?2019/11/8/562/273943
| Introduction|| |
In both science and engineering, determining the factors that significantly affect the system response is often difficult. Usually full factorial design of the experiment is used to test all possible combinations of various factors was did not effective. Furthermore, the interpretation of a large set of measurement data is difficult and may be unnecessary, because especially in engineering and practical applications, focus on only trends in how factors affect system response can be sufficient. Therefore, response surface methodology combined with central composite design (CCD) was choosen.
Human epidermal growth factor (hEGF) is a single-chain polypeptide composed of 53 amino acid residues, with six cysteine residues forming three disulfide bonds, which help fold the hEGF protein precisely, thus, it can be biologically active., The hEGF protein weighs 6.2kDa is synthesized by the hEGF-coding gene located on the 4q25-q27 chromosome, which has unique characteristics, that is, thermal resistance and is not denatured by heat up to 70°C. Moreover, hEGF is a growth factor that induces the proliferation and the metabolism of epithelial cells and has been widely used as a healing agent of various chronic wounds, and also as cosmetics to regenerate skin cells and validate skin elasticity.
Recombinant proteins produced by the Escherichia More Details coli (E. coli) host have several advantages including faster expression processes. It is because of their ability to overgrow, relatively inexpensive for the production of recombinant proteins compared to other expression systems due to its higher density on an inexpensive substrate. Moreover, its genetic has been well-characterized and the availability of a large number of mutant host strains that have certain advantages.
Expression of the hEGF recombinant (hEGF) gene with the pectate lyase B(PelB) signal peptide in E. coli BL21(DE3) secreted hEGF through periplasm to the medium. Optimized culture condition may influence the successful production of recombinant protein, not only the success of the gene insertion in the host microorganism solely., In this study, medium concentration and induction time were optimized in producing rhEGF in flask scale based on central composite design. The optimization was then followed by high cell density culture to scale-up the production of hEGF in 2 L-working volume fermentors using the optimized condition based on flask scale result.
| Materials and Methods|| |
Expression optimization using the central composite design
In the experimental design of the central composite, the three-level variables, that is, minimum (−1), medium (0), and maximum (1), were determined for both medium concentration and induction time [Table 1]. These three variables were then inserted into Minitab statistical software (Trial version) to generate the experimental design. Afterward, a total of 1mL starter culture of E. coli BL21(DE3) (pD881-PelB, synthesized in Atum, California) was introduced into 100mL Luria Bertani (LB) medium containing kanamycin (Sigma-Aldrich) in 500mL shaken flask at 37°C with 200rpm shaking rate. L-Rhamnose (Sigma-Aldrich) with optimum concentration 4mM was used as an inducer and added into the medium for certain hours (as showed in [Table 1]) after the culture started.
Production human epidermal growth factor protein in the fermenter
The production of hEGF protein was carried out by aerobic fermentation E. coli BL21(DE3) containing plasmid of pD881-PelB-hEGF in 10L fermenter (Major Science MS-F1) with working volume 2L. The fermentation process was performed in three phases, that is, (1) growth phase, this step was carried out by inserting 1% (vol/vol) inoculum into 2L (medium). Fermentation medium concentration was increased to 1.5-fold. The culture was set at 37°C, with shaking rate of 250rpm for 4h. The pH of the medium was maintained at 7.0 with the addition of 2 M sodium hydroxide (Merck) and 2 M sulfuric acid (Merck) set automatically; (2) The fed-batch phase, this phase was carried out for 3h by feeding the culture with medium containing 426g/L glycerol, 85g/L tripton, 43g/L yeast extract, and 5.3g/L magnesium sulfate heptahydrate; (3) Induction phase, this phase was performed by adding 2mM L-Rhamnose into the culture after 3h of feeding. The hEGF product collected in supernatant media after 20h induction time.
Protein characterization with SDS-PAGE tricine
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) Tricine (Biorad Power PacTM Basic) was performed to identify the secreted rhEGF. A total of 20 μL of a mixture of sample and buffer (1:1 (vol/vol)) was loaded into the gel well. In this study, a total of 7 μL protein marker biorad (25kDa) was used as a marker of protein size. Electrophoresis was performed for 2h. The gel was electroporated in 30 V for 30min before the voltages were increased to 100 V and ran for 2h. The gel was then stained at 25°C in the dark for 18h. The gel was then washed by using distilled water, and the gel was incubated in the destaining solution for 6h at 25°C. The protein band (6.2kDa) was then captured.
Quantification of recombinant human epidermal growth factor with enzyme-linked immunosorbent assay (ELISA)
The quantification of rhEGF was performed by following the procedure as described in Quantikine ELISA KIT hEGF (R and D System). Absorbance measurement was carried out at λ450 nm with correction factors at λ540 nm, and λ570 nm.
| Results and Discussion|| |
Expression optimization with the central composite design
In this study, optimization of rhEGF production from E. coli BL21(DE3) (pD881-pelB) was performed following the experimental design generated by Minitab for CCD. The variable determined for medium concentration and induction time in CCD was adapted from the previous study.
The lowest and the highest medium concentration was set into the design were 1 and 2mm, respectively [Table 1]. On the other hand, the lowest and highest induction time was set at 3 and 9h, respectively [Table 2]. Experiment in 500mL shaken flask containing 100mL culture was carried out based on the generated design. Afterward, the amount of rhEGF produced in the medium was measured and analyzed [Table 3].
|Table 2: Experimental design based on medium concentration and induction time|
Click here to view
Based on the parameters tested, a mathematical equation was generated. The equation explains the relationship between the linear influence of each parameter and its interaction. The equation was written as follows:
On the basis of the above equation, y represents the amount of rhEGF as the response of both factors. X1 represents the medium concentration, and X2 represents the induction time. The coefficient value obtained describes a relationship to the level of protein achieved. A positive coefficient value for the density of medium indicates a positive correlation between the medium concentration and the protein content produced. In contrast, a negative coefficient of induction time showed that the longer induction time could decrease the protein content produced. The effect of the variables on auto Trm activity was observed by the contour plot [Figure 1] and surface plot [Figure 2]. The plots showed that optimum condition to express rhEGF was in medium concentration 1.5-fold with 3h of induction time after the culture started. Additionally, by using the equation above, the produced protein content of the expression was predicted with 8.43 and 91.57% of the average percentage difference and the average accuracy, respectively.
|Figure 1: Contour plot of protein level (ng m/L) in function of medium concentration and induction time (h)|
Click here to view
|Figure 2: Surface plot of protein level (ng m/L) in function of medium concentration and induction time (h)|
Click here to view
Production human epidermal growth factor protein using a fermenter
The optimum condition generated from rhEGF production optimization in the shaken flask was applied in scaled up production in 10L fermenter with 2L working volume. The rhEGF output in fermenter underwent three phases. The first phase was the growth phase to grow the host E. coli BL21(DE3) (Pd881-PelB) until it reached sufficient density to produce rhEGF. The second phase was the feeding phase to increase the cell density and to prepare for the induction phase. Substances added into the feeding medium were supportive for large-scale expression that had been consumed in the growth phase. Finally, the third phase corresponds to the induction phase that was carried out 3h after feeding by adding L-Rhamnose 4mM into the medium.
Characterization of the rhEGF produced in fermenter scale can be visualized on SDS-PAGE Tricine electrophoreogram in [Figure 3]. Our result showed that rhEGF gene was successfully expressed from BL21(DE3) with a pD881-PelB expression vector. The bands support this result appeared below 10kDa, which is estimated as a rhEGF band (~6.2kDa).
|Figure 3: SDS-PAGE Tricin electrophoregram of rhEGF expression from the medium in fermenter scale: (1) Marker, (2) The soluble fraction 8h after induction, (3) Medium fraction at induction, (4) medium fraction 8h after induction, (5,6,7) Medium fraction 20h after initiation|
Click here to view
Quantification of recombinant human epidermal growth factor by ELISA
ELISA performed quantification of rhEGF expressed in the medium in fermenter scale. The hEGF standard was provided in the kit. Our result revealed that rhEGF expressed in the medium in the fermenter scale was 122.40 μg m/L [Table 3]. The result was 1000-fold higher than the shaken flask scale production. This result indicated that this strategy could be used to scale-up the production of rhEGF extracellularly from E. coli BL21(DE3) (Pd881-PelB).
| Conclusion|| |
The optimum condition of extracellular production of rhEGF from E. coli BL21(DE3) based on CCD result was a medium concentration of 1.5-fold and induction time 3h after the culture started. This optimum condition is successfully applied in the scaled up production of rhEGf in 2L working volume fermenters. The rhEGF produced from fermenter scale is 122.40 μg m/L on the 20h in the medium after induction.
We would like to thank you to Ministry of Research, Technology and Higher Education of the Republic of Indonesia Penelitian Terapan Unggulan Perguruan Tinggi (PTUPT) research grant 2019, No. 1123/UN6.O/LT/2019 for the funding of this study.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Dutka M, Ditaranto M, Løvås T. Application of a central composite design for the study of NOx emission performance of a low NOx burner. Energies 2015;8:3606-27.
Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979;48:193-216.
Eissazadeh S, Moeini H, Dezfouli MG, Heidary S, Nelofer R, Abdullah MP. Production of recombinant human epidermal growth factor in pichia pastoris. Braz J Microbiol 2017;48:286-93.
Tsang MW, Wong WKR, Hung CS, Lai KM, Tang M, Cheung EYN, et al
. Human epidermal growth factor enhances healing of diabetic foot ulcers. Emerging Treatments and Technologies 2014;26:2-7.
Jeong H, Barbe V, Lee CH, Vallenet D, Yu DS, Choi SH, et al
. Genome sequences of Escherichia coli
B strains REL606 and BL21(DE3). J Mol Biol 2009;394:644-52.
Maksum IP, Utama E, Sriwidodo S, Subroto T. Extracellular secretion of recombinant human epidermal growth factor by using trimethylamine N-Oxide reductase a (TORA) signal peptide in Escherichia coli
BL21 (DE3). J Pharm Sci Res 2017;9:1007-16.
Sriwidodo S, Subroto T, Maksum IP, Riswanto N, Rostinawati T. Extracellular secretion recombinant of human epidermal growth factor (hEGF) using pectate lyase B (PelB) signal peptide in Escherichia coli
BL21 (DE3). Int J Res Pharm Sci 2017;8:1-8.
Indriyani A, Anggraeni NI, Sriwidodo S, Maksum IP. Optimization extracellular secretion of Recombinant Human Epidermal Growth Factor (hEGF) in Escherichia coli BL21 (DE3) pD881-OmpA-hEGF by using Response Surface Method (RSM). Int J Res Pharm Sci 2019;10:1824-1831.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||Refolding of bioactive human epidermal growth factor from E. coli BL21(DE3) inclusion bodies & evaluations on its in vitro & in vivo bioactivity
| ||Iman Permana Maksum, Yosua Yosua, Ahmad Nabiel, Riyona Desvy Pratiwi, Sriwidodo Sriwidodo, Ukun M.S. Soedjanaatmadja |
| ||Heliyon. 2022; 8(4): e09306 |
|[Pubmed] | [DOI]|
||Continuous Production of Human Epidermal Growth Factor Using Escherichia coli Biofilm
| ||Mengting Li, Zhenyu Wang, Miao Zhou, Chong Zhang, Kaiqi Zhi, Shuli Liu, Xiujuan Sun, Zhi Wang, Jinle Liu, Dong Liu |
| ||Frontiers in Microbiology. 2022; 13 |
|[Pubmed] | [DOI]|
Activity and Effectiveness of Recombinant hEGF Excreted by Escherichia coli BL21 on Wound Healing in Induced Diabetic Mice
| ||Sriwidodo Sriwidodo, Iman Permana Maksum, Toto Subroto, Nasrul Wathoni, Anas Subarnas, Abd. Kakhar Umar |
| ||Journal of Experimental Pharmacology. 2020; Volume 12: 339 |
|[Pubmed] | [DOI]|